SBRT + Atezolizumab + Bevacizumab in Resectable HCC

Clinical trial NCT04857684 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04857684
Sponsor: Massachusetts General Hospital
Status: ACTIVE_NOT_RECRUITING
Phase: Early Phase 1
Study type: INTERVENTIONAL

Hepatocellular Carcinoma Resectable Hepatocellular Carcinoma

Start date: 2021-06-18
Primary completion: 2026-04-29
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.